Abstract
The interventional treatment of coronary artery disease was introduced in 1970`s by Andreas Grüntzig. The initial treatment strategy with plain old balloon angioplasty (POBA) was associated with high restenosis rates. The introduction of coronary stents, especially drug-eluting stents (DES) in 2002 has improved the results by lowering the rate of in-stent restenosis from 20-40% in the era of bare-metal stent (BMS) to 6-8%. However, in 2006 with the observation of late stent thrombosis the reputations of DES have decreased. However, improvements in stent design especially antiproliferative agents, polymeric agents as well as stent platforms improved newer generation DES. In controlled trials as well as registries the use of second-generation DES as compared to bare-metal stents (BMS) was associated with better clinical and angiographic results. A further development of these stents with use of biodegradable polymers, polymer-free stents, and biodegradable stents on the basis of poly L-lactide (PLLA) or magnesium resulted in third-generation DES and has been evaluated in preclinical and first clinical trials. However, to date, there is a lack of data comparing these thirdgeneration DES with first- and second-generatrion DES in a large scale.
Keywords: Bioabsorbable, drug-eluting stent, everolimus, next-generation, stent thrombosis, zotarolimus.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Recent Developments in Drug-Eluting Coronary Stents
Volume: 14 Issue: 3
Author(s): Mustafa Yildiz, Banu Sahin Yildiz, Mustafa Ozan Gursoy and Ibrahim Akin
Affiliation:
Keywords: Bioabsorbable, drug-eluting stent, everolimus, next-generation, stent thrombosis, zotarolimus.
Abstract: The interventional treatment of coronary artery disease was introduced in 1970`s by Andreas Grüntzig. The initial treatment strategy with plain old balloon angioplasty (POBA) was associated with high restenosis rates. The introduction of coronary stents, especially drug-eluting stents (DES) in 2002 has improved the results by lowering the rate of in-stent restenosis from 20-40% in the era of bare-metal stent (BMS) to 6-8%. However, in 2006 with the observation of late stent thrombosis the reputations of DES have decreased. However, improvements in stent design especially antiproliferative agents, polymeric agents as well as stent platforms improved newer generation DES. In controlled trials as well as registries the use of second-generation DES as compared to bare-metal stents (BMS) was associated with better clinical and angiographic results. A further development of these stents with use of biodegradable polymers, polymer-free stents, and biodegradable stents on the basis of poly L-lactide (PLLA) or magnesium resulted in third-generation DES and has been evaluated in preclinical and first clinical trials. However, to date, there is a lack of data comparing these thirdgeneration DES with first- and second-generatrion DES in a large scale.
Export Options
About this article
Cite this article as:
Yildiz Mustafa, Yildiz Sahin Banu, Gursoy Ozan Mustafa and Akin Ibrahim, Recent Developments in Drug-Eluting Coronary Stents, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1871529X14666140823121609
DOI https://dx.doi.org/10.2174/1871529X14666140823121609 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Possible Links of Age Related Hypertension and Evolution Imposed Features of Heart and Aorta
Current Aging Science Anti-inflammatory strategies in stroke: a potential therapeutic target
Current Vascular Pharmacology Inflammatory and Oxidative Stress Markers as Indicator of Atherogenesis in Rats: Antioxidants as Preventive Pharmacological Methods
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Contrast-induced Nephropathy in Non-cardiac Vascular Procedures, A Narrative Review: Part 2
Current Vascular Pharmacology The Role of Endothelin System in Cardiovascular Disease and the Potential Therapeutic Perspectives of its Inhibition
Current Topics in Medicinal Chemistry Definition of Postprandial Lipaemia
Current Vascular Pharmacology Intracerebral Hemorrhage and Diabetes Mellitus: Blood-Brain Barrier Disruption, Pathophysiology and Cognitive Impairments
CNS & Neurological Disorders - Drug Targets Pathogenesis and Treatment of Secondary Hyperparathyroidism in Dialysis Patients: The Role of Paricalcitol
Current Vascular Pharmacology Training Standards and Recommendations for Intervention on Chronic Total Occlusions
Current Cardiology Reviews Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Current Pharmaceutical Design Matrix Metalloproteinases: A Therapeutic Target in Cardiovascular Disease
Current Pharmaceutical Design Hyperandrogenism, Insulin Resistance and Hyperinsulinemia as Cardiovascular Risk Factors in Diabetes Mellitus
Current Diabetes Reviews An Interventional Pulmonologist’s Tool: Endobronchial Ultrasound- Guided Transbronchial Needle Aspiration (EBUS-TBNA) in Thoracic Disease — An Update
Current Respiratory Medicine Reviews Calixarenes in Bio-Medical Researches
Current Medicinal Chemistry Toll-Like Receptor 4 Signaling Pathway as a Potential Targets for Stroke-Induced Inflammation
Current Signal Transduction Therapy Role of Apoptosis in the Pathogenesis of Contrast Media-induced Nephropathy and Hints for its Possible Prevention by Drug Treatment
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry An Overview of Neolignans of the Genus Piper L.: Isolation Methods and Biological Activities
Mini-Reviews in Medicinal Chemistry Current Concepts in SLE Thrombocytopenia: From Pathophysiology to Therapeutic Interventions
Current Rheumatology Reviews Use of Antiplatelet Drugs in the Treatment of Acute Coronary Syndromes
Cardiovascular & Hematological Disorders-Drug Targets Intravascular Targeting of a New Anticoagulant Heparin Compound
Cardiovascular & Hematological Disorders-Drug Targets